Ellevest Inc’s Arcutis Biotherapeutics ARQT Stock Holding History

Ellevest Inc’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2	Closed	–	–	1844
2022 Q3	$0	Buy	+2	New	+$45	﹤0.01%	1590

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ellevest Inc's ARQT Position: Q4 2022 in Review

Ellevest Inc sold out of Arcutis Biotherapeutics (ARQT) in Q4 2022, closing a stake of 2 shares.

Ellevest Inc first reported a position in ARQT in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 141 funds tracked by Wall St. Rank hold ARQT as of Q4 2022.

Ellevest Inc reported no remaining Arcutis Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Ellevest Inc sold 2 Arcutis Biotherapeutics shares in Q4 2022.
Ellevest Inc first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 1 quarter.
Ellevest Inc's Arcutis Biotherapeutics position peaked at $0 in Q3 2022.
141 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2022.

Based on Ellevest Inc's 13F filing for Q4 2022, filed 3 Feb 2023.